Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 7/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 11/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 10/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 10/20 | 0.61 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL4688406 | 0.98 | PTGIR (0.61) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| Oxalic Acid SCHEMBL4693696 | 0.97 | PTGIR (0.60) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| Oxalic Acid SCHEMBL4690887 | 0.96 | PTGIR (0.64) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| SCHEMBL7886183 | 0.93 | PTGIR (0.73) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| Hydrochloric Acid SCHEMBL4743710 | 0.92 | PTGIR (0.71) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| SCHEMBL7894000 | 0.91 | PTGIR (0.70) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| SCHEMBL27028807 | 0.89 | PTGIR (0.73) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| Oxalic Acid SCHEMBL4693632 | 0.88 | ADRA2A (0.65) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| Oxalic Acid SCHEMBL4692673 | 0.85 | PTGIR (0.55) | PTGIRADRA2AADRA2BADRA2CGPR65 | |
| SCHEMBL4688349 | 0.84 | ADRA2A (0.70) | PTGIRADRA2AADRA2BADRA2CGPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0902018-B1 | 2-(Arylphenyl)amino-imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-7141584-B2 | guanidine derivatives containing phenyl and imidazole rings; useful for treating pain conditions from a wide variety of causes such as cancer, trauma, surgery, inflammation etc. | ROCHE PALO ALTO LLC (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040122053-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | BLEY KEITH ROGER (US) | 2004-06-24 | — | — | US | disclosed |
| US-6693200-B2 | IP RECEPTOR ANTAGONISTS; ANTIINFLAMMATORIES AND ANALGESICS | SYNTEX (U.S.A.) LLC | 2004-02-17 | — | — | US | disclosed |
| US-20030229123-A1 | Antiinflammatory agents; antiallergens; lipoxygenase or phospholipase inhibitors | BLEY KEITH ROGER (US) | 2003-12-11 | — | — | US | disclosed |
| US-6596876-B2 | Prostaglandin I2 inhibitors | SYNTEX (U.S.A.) LLC | 2003-07-22 | — | — | US | disclosed |
| US-20030036655-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | BLEY KEITH ROGER (US) | 2003-02-20 | — | — | US | disclosed |
| US-6472536-B1 | SUCH AS 2-(4-(4-CYCLOPENTYLOXYBENZYL)PHENYL)AMINO-IMIDAZOLINE; ANTINOCICEPTIVE AGENTS; IP RECEPTOR ANTAGONISTS; TREATING INFLAMMATORY PAIN | SYNTEX (U.S.A.) LLC | 2002-10-29 | — | — | US | disclosed |
| US-6184242-B1 | 2-(substituted-phenyl)amino-imidazoline derivatives | SYNTEX USA (LLC) | 2001-02-06 | — | — | US | disclosed |
| EP-0902018-A2 | 2-(Arylphenyl)amino-imidazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229123-A1 | Antiinflammatory agents; antiallergens; lipoxygenase or phospholipase inhibitors | LTB4R2, LTB4R, ALOX5 | PTGIR 17/4885ADRA2A 223/4885ADRA2B 256/4885 |
| US-20040122053-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | GIPR, GRK2, TBXA2R | PTGIR 34/4885ADRA2A 32/4885ADRA2B 41/4885 |
| US-20030036655-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | GIPR, TBXA2R, GRK2 | PTGIR 37/4885ADRA2A 26/4885ADRA2B 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.